Here are five points:
1. Children randomized to the device showed improvement in total body and tibial bone mineral density compared to children in the placebo group who had decreases in bone mineral density.
2. There were no adverse events with a year of twice daily 10-minute sessions.
3. Rush Simonson, chairman and CEO of Juvent, said this is the company’s first cancer patient study, and also that it plans to submit the study’s data to the FDA to secure a clearance for this new indication.
4. Juvent’s platform is used in the athletic world for recovery and healing by organizations such as The David Leadbetter Golf Academy and the NFL Alumni Association.
5. Juvent is a Riviera Beach, Fla.-based technology company that specializes in orthopedic regenerative therapies for bone and musculoskeletal health.
More articles on devices and implants:
AxioMed patient runs Boston marathon post-total disc replacement: 4 takeaways
iFuse improvements sustained 2 years post-op: 5 insights from new trial
Stryker’s net earnings up 79.5%; Orthopedics sales reach $1.1B: 9 key notes on Q1 2016
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
